Want to see SUPN full AI Analyst Report?
SUPN Stock Chart & Stats
$46.20
$1.62(3.51%)
At close: 4:00 PM EDT
$46.20
$1.62(3.51%)
Day’s Range― - ―
52-Week Range$42.45 - $59.68
Previous CloseN/A
Volume26.73K
Average Volume (3M)839.96K
Market Cap
$2.76B
Enterprise Value$2.37K
Total Cash (Recent Filing)$372.07M
Total Debt (Recent Filing)$40.17M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 10, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding58,127,014
10 Day Avg. Volume552,702
30 Day Avg. Volume839,962
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.64
Price to Sales (P/S)3.90
P/FCF Ratio61.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$65.20Price Target Upside41.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.8
Revenue Forecast (FY)$875.68M
Bulls Say, Bears Say
Bulls Say
Strong Product Revenue GrowthBroad growth across commercial products indicates expanding demand and effective execution in CNS markets. Continued momentum from Qelbree, GOCOVRI and partnered products can support revenue scale over the next several quarters.
Conservative Balance SheetA sizable cash position and absence of debt reduce refinancing pressure and provide flexibility to fund clinical development, commercial investment and potential strategic opportunities without immediate balance-sheet strain.
High Gross-margin Business ModelVery high gross margins reflect the economic advantages of branded prescription products and intellectual property. This creates meaningful operating leverage if revenue growth persists and commercial spending becomes more disciplined.
Bears Say
Unstable And Negative ProfitabilityThe shift from prior profits to substantial losses shows that strong gross margins have not yet translated into dependable bottom-line earnings. Persistent losses could constrain reinvestment capacity and increase execution sensitivity.
Weakening Free-cash-flow MomentumPositive cash generation is a strength, but the sharp deterioration in free-cash-flow growth reduces the cushion available to absorb operating losses, milestone payments and elevated investment while the portfolio expands.
Onepco Supply And Conversion RiskSupply constraints and processing friction can limit patient starts, prescriptions and revenue realization even when demand exists. Recovery depends on operational improvements and a second supplier, making execution a continuing commercial risk.
Supernus Pharmaceuticals News
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $42.45 and its highest was $59.68 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $2.76B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported $0.526 earnings per share for the quarter, beating the consensus estimate of $0.422 by $0.104.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.62.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 58,127,014 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.526 in its last earnings report, beating expectations of $0.422. Following the earnings report the stock price went up 3.07%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in SUPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Supernus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.20 (41.13% Upside)
$65.20 (41.13% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 114.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.31%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
SUPN Company Deck
SUPN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum across multiple products with robust revenue growth (total revenue +39% YoY; growth products +56% YoY), improving non-GAAP profitability, a healthy cash position (~$384M) and an advancing R&D pipeline. Offsetting these positives are meaningful increases in operating expenses (combined R&D and SG&A up ~40.8% YoY), ongoing GAAP losses (albeit reduced), supply constraints and conversion challenges for Onepco, and timing / regulatory risk related to bringing a second supplier online. Management reiterated full-year guidance ranges and emphasized continued focus on corporate development and supply backups. Overall, the positive top-line growth, improved profitability metrics, strong product-specific trends and solid balance sheet outweigh the near-term expense and supply risks.View all SUPN earnings summariesSUPN Stock 12 Month Forecast
Average Price Target
$65.20
▲(41.13% Upside)
Technical Analysis
Ownership Overview
4.33% Insiders
33.23% Mutual Funds
28.19% Other Institutional Investors
6.20% Public Companies and
Individual Investors